JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A1402 Gemcitabine HCl

Summary: Inhibits DNA synthesis,deoxycytidine analog

≥10.1 mg/mL
A2678 SU11274
2 Citation

Target: MET

Summary: C-Met inhibitor,potent and selective

≥28.4 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A1352 Zoledronic Acid

Target: Farnesyl Diphosphate Synthases

Summary: Potent nitrogen-containing bisphosphonates

insoluble in DMSO; insoluble in H2O; insoluble in EtOH
A5459 PHA-793887
1 Citation

Target: Cyclin-Dependent Kinases

Summary: Pan-Cdk inhibitor

insoluble in H2O; ≥18.05 mg/mL
A8310 PF-562271
1 Citation

Target: FAK|Pyk2

Summary: ATP-competitive FAK inhibitor, reversible

≥25.35 mg/mL
A8316 PD 0332991 (Palbociclib) HCl
5 Citation

Target: Cyclin-Dependent Kinases

Summary: CDK4/6 inhibitor,highly selective

≥14.48 mg/mL
A8320 PF-00562271

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor,potent and ATP-competitive

insoluble in EtOH; insoluble in H2O; ≥11.1 mg/mL
A8325 Tivantinib (ARQ 197)
2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL